Most Recent
Motorola has urged the High Court to reject Hytera's special leave application in their long-running dispute over the theft of Motorola's source code for its digital mobile radios.
The Full Federal Court has published its reasons for finding Hytera copied a substantial part of Motorola's source code for its digital mobile radios, saying the 15 months of labour the China-based company saved from the copying reinforced its conclusion.
Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers.
AstraZeneca has attacked generic drugmaker Pharmacor’s challenge to a patent extension for its diabetes drug Forxiga, telling a judge that it hinges on the false notion that the protected IP is limited to a single molecule.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
China-based Hytera Communications wants the High Court to overturn a finding that it stole Motorola's source code for its digital mobile radios, arguing the appeal raises important issues about how "substantial part" should be assessed under the Copyright Act.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.